惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

MyScale Blog
MyScale Blog
博客园 - 司徒正美
A
About on SuperTechFans
Vercel News
Vercel News
H
Hackread – Cybersecurity News, Data Breaches, AI and More
爱范儿
爱范儿
I
InfoQ
freeCodeCamp Programming Tutorials: Python, JavaScript, Git & More
博客园_首页
Google DeepMind News
Google DeepMind News
T
Tailwind CSS Blog
奇客Solidot–传递最新科技情报
奇客Solidot–传递最新科技情报
F
Fortinet All Blogs
S
SegmentFault 最新的问题
阮一峰的网络日志
阮一峰的网络日志
D
Docker
钛媒体:引领未来商业与生活新知
钛媒体:引领未来商业与生活新知
G
Google Developers Blog
Stack Overflow Blog
Stack Overflow Blog
M
MIT News - Artificial intelligence
Jina AI
Jina AI
H
Help Net Security
量子位
IT之家
IT之家

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
BioStem Technologies, Inc. (BSEM) Q1 2026 Earnings Call T...
2026-05-15 · via All Articles on Seeking Alpha

BioStem Technologies, Inc. (BSEM) Q1 2026 Earnings Call May 14, 2026 4:30 PM EDT

Company Participants

Jason Matuszewski - CEO, President, Secretary & Chairman
Barry Hassett - Chief Commercial Officer
Brandon Poe - CFO

Conference Call Participants

Swayampakula Ramakanth - H.C. Wainwright & Co, LLC, Research Division
Michael Matson - Needham & Company, LLC, Research Division
Bruce Jackson - The Benchmark Company, LLC, Research Division

Presentation

Operator

Ladies and gentlemen, thank you for standing by. My name is Abby, and I will be your conference operator today. At this time, I would like to welcome everyone to the BioStem Technologies First Quarter 2026 Earnings Call.

[Operator Instructions] Thank you. And I would now like to turn the conference over to Hannah Geoffrey, Investor Relations. You may begin.

Unknown Executive

Good afternoon, everyone, and thank you for joining our conference call to discuss BioStem's First quarter 2026 financial results and corporate highlights. Leading the call today will be Jason Matuszewski, the company's Chairman and Chief Executive Officer; Barry Hassett, the company's Chief Commercial Officer; and Brandon Poe, the company's Chief Financial Officer.

Before we begin, I'd like to remind everyone that our remarks may contain forward-looking statements based on management's current expectations. These involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated. These risks are described in our filings with OTC Markets. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date made. The company undertakes no obligation to update them unless required by law.

Finally, this call also includes references to non-GAAP financial measures. A reconciliation to comparable GAAP measures and related information can be found in our earnings press release posted on the Investor Relations section of BioStem's website.

With that, I'd now like to turn